source
- GSK signs $1 billion siRNA partnership with China's SiranBio to target obesityGSK is expanding its cardiometabolic portfolio by entering a new collaboration with Chinese biotech SiranBio. The agreement is valued at $1 billion in biobucks and focuses on developing siRNA ther…
- Novo Nordisk shares rise as Wegovy updates improve earnings outlookNovo Nordisk reported that recent data on its obesity drug Wegovy were less negative than expected, helping the company’s earnings. The improved outlook lifted Novo Nordisk’s share price, narrowin…